GLP-1 Receptor Agonists (GLP-RAs) have transformed the treatment of diabetes and obesity and are an important advance in the successful treatment of these and maybe other chronic diseases. These medicines were originally developed to treat diabetes, with Ozempic, a semaglutide, released in 2016. In 2023 these drugs became known more generally because of their off-target effect of stimulating weight loss (1).
GLP-1 stands for “glucagon-like peptide 1”, a peptide hormone that is released from cells in the small intestine in the presence of nutrients. One of its functions is to mediate the secretion of insulin in response to these nutrients by activating the GLP-1 receptor in the pancreas.
What are some of the off-target effects of GLP-1RAs on aging that researchers are uncovering?
Several research studies of GLP-1 RAs have indicated that not only do they have the positive effects of regulating blood glucose and weight, but they have also shown benefits that include reduction of heart, liver and kidney diseases. A study published in Nature in 2026 by Feng and colleagues (2) now presents evidence that these drugs may even affect aging in a mouse model, attenuating age effects and maintaining cognition. The results are promising. The scientists looked at several recognized hallmarks of aging, including stem cell attrition, inflammation, protein folding and stability issues, and genomic stability. For both hematopoietic stem cells (HSCs) and neural stem cells (NSCs), the authors found that treatment with semaglutide increased the regenerative capacity of the respective tissues. Furthermore, they found that in semaglutide treatment increased expression of mitochondria-related genes and the oxidative-stress response genes, increased ATP content, and reduced levels of reactive oxygen species.
After determining that semaglutide reduced hallmarks of aging in female mice, the scientists asked whether it worked through the same mechanism as caloric restriction. To answer this question, they divided mice into three groups: vehicle control, semaglutide treatment, and 24% caloric restriction. They first observed that although the semaglutide and caloric restriction groups consumed similar amounts of food each day, the calorie-restricted mice tended to eat all their food at once and then fast, while the semaglutide-treated mice ate smaller amounts throughout the day. Calorie-restricted mice showed hunger-driven behaviors and metabolic adaptations; semaglutide-treated mice showed suppressed appetite and lacked the feeding-related metabolic and activity rhythms associated with caloric restriction. In addition, the authors noted that semaglutide-treated mice showed many of the same functional gains as calorie-restricted mice, along with additional cognitive and metabolic benefits not seen in the calorie-restricted group.
What does the mouse study mean?
This study was conducted with mice under very carefully controlled laboratory conditions. It’s a great and extremely thorough study, but mouse studies do not always translate directly to human biology. In fact, in drug discovery research, the failure rate for the translation of a newly discovered drug from animal testing to human treatments remains at over 92% (3). Between 1995 and 2010, around 300 drugs and other interventions looked promising in a mouse mode of Alzheimer disease have not proven effective in human trials (4). However, studies in mice (and zebrafish, fruit flies and nematodes) can clue us into important basic biology that we can use to develop better therapeutics, and, indeed, mouse models have been used to successfully develop drugs for polycystic kidney disease and other pathologies (5). There is tremendous learning that can be applied to our understanding of human cellular physiology from model system research.
That said, I cringe when I see social media posts and even reports in mainstream media outlets that ignore all the caveats and conditions of the scientific work and just claim “aging reversed”. Or articles that lead with a sensational headline and leave all the gory details buried in the text that almost no one reads.
This was a great study, well designed and extremely thorough. Now, each one of the phenotypic effects these researchers noticed in their mouse model needs to be dissected at the cellular and molecular level, in mice, in cell culture, in organoids. That’s probably 5 or 6 completely new research papers for each observed phenotypic effect before we have anything close to a complete story. What pathways are affected? What molecules in those pathways are involved? What happens in cell cultures or tissue systems affected?
Science is incremental. Small steps. Little bits of learning stacked together to get to a larger truth. Maybe that doesn’t give the world instant gratification, but it’s the scientific process, and it works. So, I return to the opening question: Can GLP-1 RAs help you live longer? Well, Maybe—if you are a female C57BL/6 mouse living in highly controlled laboratory conditions.
Literature Cited
- Nutting, J. (2023) How Does Ozempic Work? The Mechanism of Action of Semaglutide and Other GLP-1 Receptor Agonists. Promega Connections [Internet: How Does Ozempic Work? The Mechanism of Action of Semaglutide and Other GLP-1 Receptor Agonists – Promega Connections Accessed 9/15/2026]
- Feng, Y., Barthez, M., Wang, Y. et al (2026) Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature 657, 469–476. [Internet: https://doi.org/10.1038/s41586-026-10940-7 Accessed 9/15/2026]
- Marshall, L. J. (2023) Poor Translatability of Biomedical Research Using Animals–A Narrative Review Alternatives to Laboratory Animals. Alternatives to Laboratory Animals. 2023;51(2):102-135 https://journals.sagepub.com/doi/10.1177/02611929231157756
- Zahs, K.R. and Ashe, K.H. (2010) “Too much good news”—are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer disease? Trends in Neuroscience 33(18):381–389. https://www.cell.com/trends/neurosciences/fulltext/S0166-2236(10)00078-0
- Wilk, E. J. et al. (2023) Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 mode gene expression reversion. Mol. Med. 29:67. https://pmc.ncbi.nlm.nih.gov/articles/PMC10201779/
Michele Arduengo, PhD
Latest posts by Michele Arduengo, PhD (see all)
- Can GLP-1 RAs Help Me Live Longer? Well… - September 17, 2026
- What Can We Do to Make Your Work Easier? Addressing the Challenges of Working with Primary Antibodies - September 15, 2026
- From Chromosomes to the Brain: How HaloTag Is Expanding What We Can See - August 25, 2026
